Expert dermatologists have published their perspective regarding the use of Stelara™ for Psoriasis via Vivacare, a patient education company that provides dermatologists with tools to educate their patients and the public about skin conditions and offer skin care advice.
According to Steve Feldman, M.D., PhD, Professor of Dermatology at Wake Forest University Medical Center, "Stelara appears to be an excellent new option for moderate-to-severe psoriasis, offering patients who have failed other (psoriasis) treatments new hope, and offering the most convenient options yet for treating severe disease. The primary benefits are high efficacy and, so far, good safety (measured over about 2 years of use).”
Stelara™ is the most recent biologic to become available to people with psoriasis, a chronic, autoimmune disease that appears on the skin. The medication is administered twice in the first month, followed by dosing just four times per year. The relatively long duration of relief between treatments (only 5 doses per year) is perceived has having significant advantages. Stelara™ also has a unique mechanism of action by selectively targeting immune system signals called "cytokines" that are responsible for the inflammation seen with psoriasis, specifically interleukin-12 (IL-12) and interleukin 23 (IL-23). Other biologics regulate different immune system components, such as T-cells or tumor necrosis factor (TNF).